Characteristics of CALM-AF10+ non-T ALs
UPN . | Sex/age . | WBC . | Med . | H/S . | Clinical course . | AF10 nucleotide . | Diagnosis . | Positive CD . | Negative CD . | TCRδ . | TCRγ . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3821 | F/78 | 126 | Pos | Neg | CR (ALL), alive 96 mo | 883/979 | B-ALL my+ | 7, 34, 117, 65, 56, 19, 22, cyt79a | cyt3, 2, 5, 4, MPO, 13, 33, cytμ, 10, 41 | D2-J1 and D2-J1 | V11-J1/2 and V11-J1/2 |
| 4021 | M/18 | 218 | Pos | Pos | CR-BMT (ALL), alive 12 mo | 883/979 | AUL | 7, 34, 33, 19, HLA-DR | cyt3, 2, 5, 4, 8, MPO, 13, 65, cyt22, 22, cyt79a, 10, TdT | D2-J1 and D2-J1 | V9-J1/2 and V11-J1/2 |
| 3469 | M/18 | 1.2 | Neg | Pos | NR (ALL), CR-BMT (AML), alive 24 mo | 883/979 | AUL | 7, 34, 5 | cyt3, 2, 4, MPO, 13, 33, 19, cyt22 | D2-J1 | Vfl-J1/2 and V9-JP1/2 |
| 3883 | F/29 | 26 | Neg | Neg | CR-BMT (AML), alive 104 mo | 589 | AUL | 7, 34, 38, HLA-DR | cyt3, 2, 5, 4, MPO, 13, 33, 19, cyt22, cytμ, 10, 41 | V1-J1 and D2-J1 | Vfl-J1/2 and Vfl-J1/2 |
| 1592 | M/25 | 170 | Pos | Neg | CR (AML), Rel, D (8 mo) | 883/979 | AML (M1) | 7, 4, MPO, 117, 13, 33, 65, HLA-DR | cyt3, 2, 5, 19, 10, 41, 34 | D2-D3 | V11-JP1/2 and V11-JP1/2 |
| 4458 | F/16 | 122 | Neg | Pos | CR-BMT (AML), D (6 mo) | 424 | AML (M1) | 7, 34, MPO, 33, 15, HLA DR | cyt3, 2, 5, 4, 13, 117, 19, cyt22, cμ, 10, 41 | D2-J1 | ND |
| U937 | — | — | — | — | — | 424 | — | — | — | V2-D3 | GL |
UPN . | Sex/age . | WBC . | Med . | H/S . | Clinical course . | AF10 nucleotide . | Diagnosis . | Positive CD . | Negative CD . | TCRδ . | TCRγ . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 3821 | F/78 | 126 | Pos | Neg | CR (ALL), alive 96 mo | 883/979 | B-ALL my+ | 7, 34, 117, 65, 56, 19, 22, cyt79a | cyt3, 2, 5, 4, MPO, 13, 33, cytμ, 10, 41 | D2-J1 and D2-J1 | V11-J1/2 and V11-J1/2 |
| 4021 | M/18 | 218 | Pos | Pos | CR-BMT (ALL), alive 12 mo | 883/979 | AUL | 7, 34, 33, 19, HLA-DR | cyt3, 2, 5, 4, 8, MPO, 13, 65, cyt22, 22, cyt79a, 10, TdT | D2-J1 and D2-J1 | V9-J1/2 and V11-J1/2 |
| 3469 | M/18 | 1.2 | Neg | Pos | NR (ALL), CR-BMT (AML), alive 24 mo | 883/979 | AUL | 7, 34, 5 | cyt3, 2, 4, MPO, 13, 33, 19, cyt22 | D2-J1 | Vfl-J1/2 and V9-JP1/2 |
| 3883 | F/29 | 26 | Neg | Neg | CR-BMT (AML), alive 104 mo | 589 | AUL | 7, 34, 38, HLA-DR | cyt3, 2, 5, 4, MPO, 13, 33, 19, cyt22, cytμ, 10, 41 | V1-J1 and D2-J1 | Vfl-J1/2 and Vfl-J1/2 |
| 1592 | M/25 | 170 | Pos | Neg | CR (AML), Rel, D (8 mo) | 883/979 | AML (M1) | 7, 4, MPO, 117, 13, 33, 65, HLA-DR | cyt3, 2, 5, 19, 10, 41, 34 | D2-D3 | V11-JP1/2 and V11-JP1/2 |
| 4458 | F/16 | 122 | Neg | Pos | CR-BMT (AML), D (6 mo) | 424 | AML (M1) | 7, 34, MPO, 33, 15, HLA DR | cyt3, 2, 5, 4, 13, 117, 19, cyt22, cμ, 10, 41 | D2-J1 | ND |
| U937 | — | — | — | — | — | 424 | — | — | — | V2-D3 | GL |
Immunophenotype is shown as positive and negative CD antigens. Type of TCRδ and TCRγ rearrangement is shown for each case. my indicates myeloid; MPO, myeloperoxidase; cyt, cytoplasmic; —, not applicable. Other abbreviations are explained in Table 1 and the text